Stocks · News reference
Leerink Partners analyst David Risinger initiates coverage on Entera Bio (NASDAQ:ENTX) with a Outperform rating and announces Price Target of $9.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia)These
U.S. futures rose, but Alignment Healthcare plunged 24% after a Medicare contract downgrade; telecom and other stocks also fell premarket.
Filed: 2026-10-06 AccNo: 0001178913-26-004720 Size: 225 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.